Lilly's Zepbound Boosts Taltz Response in Psoriasis Study
Lilly reports Zepbound (tirzepatide) enhanced Taltz (ixekizumab) efficacy in a psoriasis study, a signal for combination therapy in metabolic-psoriatic disease.
Topic
Glp 1 Receptor Agonist
Topic
Glp 1 Receptor Agonist
GLP-1 Combination Therapy Signals New Benefits in Psoriasis
NewsNation reports GLP-1 combination therapy may unlock new benefits for psoriasis patients, extending the metabolic-skin overlap…